Sanara Medtech INC Form 4 insider transactions

Sanara MedTech Inc. CEO Seth D. Yon was granted 28,563 shares of restricted common stock, vesting over three years.

A Sanara MedTech officer had shares withheld to cover tax obligations from restricted stock vesting, a routine transaction.

Sanara MedTech Inc. Director Eric D. Tanzberger was granted 3,590 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Sanara MedTech Inc. Director Ann Beal Salamone was granted 2,809 shares of restricted common stock, aligning her interests with long-term shareholder value.

Sanara MedTech Inc. Director Sara N. Ortwein was granted 3,277 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan, aligning her interests with shareholder value.

Sanara MedTech Inc. Director Keith G. Myers was granted 2,965 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Sanara MedTech Inc. Director Eric Major was granted 3,277 shares of restricted common stock, vesting by May 22, 2026, as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Sanara MedTech Inc. Director Robert Andrew DeSutter received a grant of 3,746 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Sanara MedTech Inc. Director Roszell Mack III was granted 3,433 shares of restricted common stock, vesting by May 2026, as part of the company's 2024 Long-Term Incentive Plan.

Seth D. Yon, a top executive at Sanara MedTech, used company stock to cover tax obligations arising from vested restricted stock.

Chief Operating Officer Jacob A. Waldrop reports a transaction involving the withholding of Sanara MedTech Inc. common stock to cover tax obligations related to vested restricted stock.

Michael McNeil, Ch. Acct. & Ch. Admin. Officer of Sanara MedTech Inc., reports the withholding of company stock to cover tax obligations related to the vesting of restricted stock.

Michael D. McNeil, Ch. Acct. & Ch. Admin. Officer of Sanara MedTech Inc., reports acquisition of 1,486 shares of restricted stock.

Elizabeth Taylor, CFO of Sanara MedTech Inc., reports the acquisition of 5,382 shares of restricted stock granted under the company's 2024 Omnibus Long-Term Incentive Plan.

Michael D. McNeil, Ch. Acct. & Ch. Admin Officer of Sanara MedTech Inc., reports the acquisition of 5,037 shares of restricted stock granted under the company's 2024 Omnibus Long-Term Incentive Plan.

Ronald T. Nixon, CEO of Sanara MedTech Inc., reports acquisition of restricted stock and details of beneficial ownership through related entities.

Jacob Waldrop, Chief Operating Officer of Sanara MedTech Inc., reports acquisition of restricted stock and disposal of common stock.

Keith G. Myers, a director at Sanara MedTech Inc., acquired 1,975 shares of restricted stock on November 11, 2024, as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Director Sara N. Ortwein reports receiving a grant of 3,440 shares of restricted stock and disposing of 17,522 shares of common stock.

Director Roszell Mack III reports receiving a grant of 3,604 shares of restricted stock and disposing of 13,101 shares of common stock on June 12, 2024.

Director Eric Tanzberger reports acquisition and disposal of Sanara MedTech shares on June 12, 2024, according to a Form 4 filing.

Director James W. Stuckert reports acquiring 3,440 shares of restricted stock in Sanara MedTech Inc.

Director Ann Beal Salamone reports acquisition of restricted stock and disposal of common stock in Sanara MedTech Inc.

Sanara MedTech CEO Ronald T. Nixon received 10,812 shares of restricted stock on June 12, 2024, vesting on June 12, 2025, while also reporting indirect ownership through related entities.

Director Robert Andrew DeSutter acquired 3,932 shares of restricted stock in Sanara MedTech Inc. on June 12, 2024.

Director Eric D. Major reports receiving a grant of 3,440 shares of restricted stock and disposing of 6,109 shares of common stock in Sanara MedTech Inc.

Jacob A. Waldrop, Chief Operating Officer of Sanara MedTech Inc., reports the acquisition of 3,101 shares of restricted stock.

CEO Zachary Fleming reports the acquisition of 12,693 shares of restricted stock and the disposal of 48,854 shares of common stock on March 7, 2024.

Michael McNeil, CFO of Sanara MedTech Inc., reports the acquisition of 4,650 shares of restricted stock granted under the company's 2014 Omnibus Long Term Incentive Plan.

Sanara MedTech's CEO, Zachary Fleming, reports the withholding of shares to cover tax obligations related to vesting restricted stock.